Lilly takes it to Biogen, and the Alzheimer’s events stack up
Lilly's remarkable decision to run a head-to-head trial of donanemab versus Aduhelm spells another big readout for the amyloid targeting space.
Incyte and Seagen face tricky launches
Black box warnings could limit the sales of their newly approved therapeutics.
Breakthrough device reimbursement rule on the rocks
Despite industry outcry, new data question how relevant the rule would have been anyway.
Jaks capped in arthritis – but the FDA might not be finished
The US regulator’s restrictions spell trouble for the Jak inhibitor class – though there will be beneficiaries.
EQRX vows to slash drug prices where others have failed
Promises to act on pharma’s financial toxicity increasingly seem to lack bite, but EQRX promises to follow its words with real action.
Biogen and the social contract
The pricing of Aduhelm has been compared to that of Sovaldi, but this ignores the fact that Sovaldi actually worked.
